Troy S M, Rudolph R, Mayersohn M, Chiang S T
Wyeth-Ayerst Research, Philadelphia, Pennsylvania 19101, USA.
J Clin Pharmacol. 1998 May;38(5):467-74. doi: 10.1002/j.1552-4604.1998.tb04455.x.
The influence of cimetidine on the disposition pharmacokinetics of the antidepressant drug, venlafaxine, and its active metabolite, O-desmethylvenlafaxine, was examined in 18 healthy young men and women. The steady-state pharmacokinetic profiles of venlafaxine and O-desmethylvenlafaxine were evaluated during a 24-hour period after 5 days of treatment with venlafaxine (50 mg three times a day) and during a second 24-hour period after 5 days of combination treatment with venlafaxine (50 mg three times a day) and cimetidine (800 mg once a day). The apparent oral clearance of venlafaxine decreased significantly in the presence of cimetidine and the average steady-state plasma concentration of venlafaxine increased significantly in the presence of cimetidine, but there were no changes in the corresponding concentrations of the active metabolite. However, O-desmethylvenlafaxine exhibits pharmacologic activity that is approximately equimolar to that of venlafaxine, and the sum of venlafaxine plus O-desmethylvenlafaxine plasma concentrations was increased by an average of only 13%. Therefore, the effect of cimetidine coadministration is not expected to result in clinically important alterations in the response to venlafaxine in patients with depression. This may not be true, however, for patients with compromised hepatic metabolic function.
在18名健康青年男女中研究了西咪替丁对抗抑郁药文拉法辛及其活性代谢物O-去甲基文拉法辛处置药代动力学的影响。在接受文拉法辛(每日3次,每次50mg)治疗5天后的24小时期间,以及在文拉法辛(每日3次,每次50mg)与西咪替丁(每日1次,800mg)联合治疗5天后的第二个24小时期间,评估了文拉法辛和O-去甲基文拉法辛的稳态药代动力学特征。在西咪替丁存在的情况下,文拉法辛的表观口服清除率显著降低,且在西咪替丁存在的情况下,文拉法辛的平均稳态血浆浓度显著升高,但活性代谢物的相应浓度没有变化。然而,O-去甲基文拉法辛表现出与文拉法辛近似等摩尔的药理活性,且文拉法辛加O-去甲基文拉法辛血浆浓度之和平均仅增加13%。因此,预计联合使用西咪替丁不会导致抑郁症患者对文拉法辛的反应出现具有临床意义的改变。然而,对于肝代谢功能受损的患者,情况可能并非如此。